文献速递前列腺癌

新诊断中危局限性前列腺癌同位素骨扫描路径与指征的建立——来自大型同期队列的结果

Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
PubMed 文献 · BJU Int · 2017-04-19

该研究回顾性分析2002至2015年间2720例新诊断前列腺癌患者,按D'Amico分类评估骨扫描阳性模式。976例中危患者中仅1例骨扫描阳性,且仅限于Gleason主要模式4者;Gleason主要模式3且PSA<20 ng/mL者骨扫描阴性预测值为100%。作者认为中危且Gleason主要模式3者可安全避免骨扫描,并支持EAU指南推荐。

要点

  • 中危前列腺癌且Gleason主要模式3者骨扫描均阴性,阴性预测值100%。
  • 中危Gleason主要模式4且PSA<20 ng/mL者骨扫描阳性率为6%。
  • 将骨扫描限制于高危及中危Gleason主要模式4者,单中心每年可避免68例骨扫描。

核心结论

  • 中危前列腺癌且Gleason主要模式3者可安全避免分期骨扫描,骨扫描应限于所有高危患者及中危Gleason主要模式4者,从而强化EAU指南当前推荐。

研究设计与样本

  • 回顾性分析2002至2015年间2720例新诊断前列腺癌患者,所有患者经专科多学科团队会议讨论并前瞻性录入数据库,按D'Amico分类,所有中危和高危患者均行盆腔磁共振成像和骨扫描(除非有禁忌)。

主要发现

  • 976例D'Amico中危患者中99例为Gleason主要模式4,仅1例骨扫描阳性;中危Gleason主要模式3者无骨扫描阳性。
  • PSA<20 ng/mL且Gleason主要模式4 vs 3的骨扫描阳性率分别为6%和0%,Gleason主要模式3且PSA<20 ng/mL者骨扫描阴性预测值为100%。
  • 146例临床T分期高危、PSA<20 ng/mL且Gleason评分<8的患者中8例骨扫描阳性,8例均为Gleason主要模式4。
  • 将骨扫描限制于高危+中危Gleason主要模式4人群,单中心每年可避免68例骨扫描。

关键数值与推荐

  • 中危Gleason主要模式3且PSA<20 ng/mL者骨扫描阴性预测值为100%。
  • 中危Gleason主要模式4且PSA<20 ng/mL者骨扫描阳性率为6%。
  • 中危Gleason主要模式3者骨扫描阳性率为0%。

临床怎么用

  • 作者认为中危前列腺癌且Gleason主要模式3者可安全避免分期骨扫描。
  • 作者认为骨扫描应限于所有高危患者及中危Gleason主要模式4者,并讨论了结合新Gleason分级分组扩展骨扫描推荐。

局限性

  • 原文指出局限性为无骨转移的组织学确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To establish the pattern of isotope bone scan (BS) positivity in a large contemporaneous cohort of patients with newly diagnosed localised prostate cancer and compare with the European Association of Urology (EAU) guidelines, as imaging guidelines and clinical practice for using BS to stage newly diagnosed patients with intermediate-risk localised prostate cancer are not uniform in the literature. PATIENTS AND METHODS: All patients with newly diagnosed prostate cancer were discussed in a specialist multidisciplinary team meeting and were prospectively entered in a database. Patients were categorised based on D'Amico classification. All intermediate- and high-risk patients had pelvic magnetic resonance imaging and BS unless contraindicated. The BS positivity in each group was analysed and the negative predictive value (NPV) calculated. A cohort of 2720 patients between 2002 and 2015 was retrospectively analysed. RESULTS: Of 976 patients in the D'Amico intermediate-risk category, 99 had primary Gleason pattern 4. Only one of the 99 patients had a positive BS and there were no positive BS in patients with Gleason primary pattern 3 in the intermediate-risk category. On subgroup analysis, based on prostate-specific antigen (PSA) level and Gleason grade alone, the BS-positivity rate in patients with a PSA level of <20 ng/mL and Gleason primary pattern 4 vs 3 was 6% and 0%, respectively, resulting in 100% NPV for a positive BS with Gleason primary pattern 3 and a PSA level of <20 ng/mL. The importance of clinical T stage (cT) was also noted, as eight of 146 patients had positive BS, who were high risk on cT stage, with a PSA level of <20 ng/mL and Gleason score <8. All eight patients had Gleason primary pattern 4. By limiting BS to the population at risk (all high-risk + intermediate-risk with primary pattern 4), 68 BS per year could have been avoided in a single centre. A limitation was that there was no histological confirmation of bony metastases. Extending the BS recommendation considering the new Gleason Grade Grouping is discussed. CONCLUSION: This study confirms that a staging BS can be safely avoided in patients with intermediate-risk prostate cancer with Gleason primary pattern 3 and to limit performing BS in all high-risk prostate cancer and in the intermediate-risk group when the primary Gleason pattern is 4, thereby reinforcing the current recommendations of the EAU guidelines.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. KandaSwamy GV, Bennett A, Narahari K, et al. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort. BJU Int. 2017. PMID: 28317247. doi:10.1111/bju.13850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。